S&P 500   3,925.69 (-0.58%)
DOW   31,919.64 (-0.58%)
QQQ   307.57 (-0.70%)
AAPL   158.48 (-0.28%)
MSFT   277.78 (+0.04%)
META   205.03 (+0.37%)
GOOGL   104.57 (-0.98%)
AMZN   97.03 (-1.70%)
TSLA   188.31 (-2.03%)
NVDA   264.44 (-2.75%)
NIO   8.89 (-4.10%)
BABA   86.49 (-0.03%)
AMD   97.14 (-3.13%)
T   18.47 (+0.05%)
F   11.37 (-0.44%)
MU   60.96 (-0.62%)
CGC   1.90 (-0.75%)
GE   91.06 (-0.58%)
DIS   93.30 (-2.64%)
AMC   4.39 (-1.79%)
PFE   39.99 (-0.47%)
PYPL   72.88 (+0.44%)
NFLX   326.51 (+1.92%)
S&P 500   3,925.69 (-0.58%)
DOW   31,919.64 (-0.58%)
QQQ   307.57 (-0.70%)
AAPL   158.48 (-0.28%)
MSFT   277.78 (+0.04%)
META   205.03 (+0.37%)
GOOGL   104.57 (-0.98%)
AMZN   97.03 (-1.70%)
TSLA   188.31 (-2.03%)
NVDA   264.44 (-2.75%)
NIO   8.89 (-4.10%)
BABA   86.49 (-0.03%)
AMD   97.14 (-3.13%)
T   18.47 (+0.05%)
F   11.37 (-0.44%)
MU   60.96 (-0.62%)
CGC   1.90 (-0.75%)
GE   91.06 (-0.58%)
DIS   93.30 (-2.64%)
AMC   4.39 (-1.79%)
PFE   39.99 (-0.47%)
PYPL   72.88 (+0.44%)
NFLX   326.51 (+1.92%)
S&P 500   3,925.69 (-0.58%)
DOW   31,919.64 (-0.58%)
QQQ   307.57 (-0.70%)
AAPL   158.48 (-0.28%)
MSFT   277.78 (+0.04%)
META   205.03 (+0.37%)
GOOGL   104.57 (-0.98%)
AMZN   97.03 (-1.70%)
TSLA   188.31 (-2.03%)
NVDA   264.44 (-2.75%)
NIO   8.89 (-4.10%)
BABA   86.49 (-0.03%)
AMD   97.14 (-3.13%)
T   18.47 (+0.05%)
F   11.37 (-0.44%)
MU   60.96 (-0.62%)
CGC   1.90 (-0.75%)
GE   91.06 (-0.58%)
DIS   93.30 (-2.64%)
AMC   4.39 (-1.79%)
PFE   39.99 (-0.47%)
PYPL   72.88 (+0.44%)
NFLX   326.51 (+1.92%)
S&P 500   3,925.69 (-0.58%)
DOW   31,919.64 (-0.58%)
QQQ   307.57 (-0.70%)
AAPL   158.48 (-0.28%)
MSFT   277.78 (+0.04%)
META   205.03 (+0.37%)
GOOGL   104.57 (-0.98%)
AMZN   97.03 (-1.70%)
TSLA   188.31 (-2.03%)
NVDA   264.44 (-2.75%)
NIO   8.89 (-4.10%)
BABA   86.49 (-0.03%)
AMD   97.14 (-3.13%)
T   18.47 (+0.05%)
F   11.37 (-0.44%)
MU   60.96 (-0.62%)
CGC   1.90 (-0.75%)
GE   91.06 (-0.58%)
DIS   93.30 (-2.64%)
AMC   4.39 (-1.79%)
PFE   39.99 (-0.47%)
PYPL   72.88 (+0.44%)
NFLX   326.51 (+1.92%)
NASDAQ:ENTX

Entera Bio - ENTX Stock Forecast, Price & News

$1.05
-0.01 (-1.07%)
(As of 03/24/2023 11:21 AM ET)
Add
Compare
Today's Range
$1.00
$1.10
50-Day Range
$0.83
$1.44
52-Week Range
$0.47
$3.00
Volume
19,328 shs
Average Volume
246,592 shs
Market Capitalization
$30.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Entera Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
614.3% Upside
$7.50 Price Target
Short Interest
Healthy
0.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.75mentions of Entera Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Medical Sector

815th out of 989 stocks

Biological Products, Except Diagnostic Industry

140th out of 166 stocks


ENTX stock logo

About Entera Bio (NASDAQ:ENTX) Stock

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Receive ENTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

ENTX Stock News Headlines

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Entera Bio Ltd. (ENTX)
Centillion Fund Inc. Ups Stake in Entera Bio (ENTX)
ENTX Entera Bio Ltd.
See More Headlines
Receive ENTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

ENTX Company Calendar

Last Earnings
11/11/2021
Today
3/24/2023
Next Earnings (Estimated)
3/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTX
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.50
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+614.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-12,190,000.00
Net Margins
-1,796.49%
Pretax Margin
-4,901.05%

Debt

Sales & Book Value

Annual Sales
$570,000.00
Book Value
$0.95 per share

Miscellaneous

Free Float
27,321,000
Market Cap
$30.24 million
Optionable
Not Optionable
Beta
1.79

Key Executives

  • Miranda J. Toledano
    Chief Executive Officer & Director
  • Hillel Galitzer
    Chief Operating Officer
  • Dana Yaacov Garbeli
    Chief Financial Officer
  • Arthur C. Santora
    Chief Medical Officer
  • Irena Ben-Yakar
    Internal Auditor













ENTX Stock - Frequently Asked Questions

Should I buy or sell Entera Bio stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ENTX shares.
View ENTX analyst ratings
or view top-rated stocks.

What is Entera Bio's stock price forecast for 2023?

2 equities research analysts have issued 1 year target prices for Entera Bio's shares. Their ENTX share price forecasts range from $5.00 to $10.00. On average, they anticipate the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 614.3% from the stock's current price.
View analysts price targets for ENTX
or view top-rated stocks among Wall Street analysts.

How have ENTX shares performed in 2023?

Entera Bio's stock was trading at $0.73 at the beginning of the year. Since then, ENTX stock has increased by 43.8% and is now trading at $1.05.
View the best growth stocks for 2023 here
.

Are investors shorting Entera Bio?

Entera Bio saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 86,700 shares, an increase of 181.5% from the February 13th total of 30,800 shares. Based on an average daily volume of 219,900 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.4% of the shares of the company are sold short.
View Entera Bio's Short Interest
.

When is Entera Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our ENTX earnings forecast
.

How were Entera Bio's earnings last quarter?

Entera Bio Ltd. (NASDAQ:ENTX) released its quarterly earnings results on Thursday, November, 11th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.03. The firm had revenue of $0.14 million for the quarter. Entera Bio had a negative trailing twelve-month return on equity of 27.72% and a negative net margin of 1,796.49%.

What other stocks do shareholders of Entera Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA).

When did Entera Bio IPO?

(ENTX) raised $11 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.

What is Entera Bio's stock symbol?

Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."

Who are Entera Bio's major shareholders?

Entera Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (1.03%), Renaissance Technologies LLC (0.48%) and Millennium Management LLC (0.16%). Insiders that own company stock include Miranda Jayne Toledano, Ramesh Ratan, Ron Mayron, Sean Ellis and Yonatan Malca.
View institutional ownership trends
.

How do I buy shares of Entera Bio?

Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Entera Bio's stock price today?

One share of ENTX stock can currently be purchased for approximately $1.05.

How much money does Entera Bio make?

Entera Bio (NASDAQ:ENTX) has a market capitalization of $30.24 million and generates $570,000.00 in revenue each year. The company earns $-12,190,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

How can I contact Entera Bio?

Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The official website for the company is www.enterabio.com. The company can be reached via phone at (722) 532-7151 or via email at investorrelations@enterabio.com.

This page (NASDAQ:ENTX) was last updated on 3/24/2023 by MarketBeat.com Staff